Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma
Conclusion: Lenvatinib had potential benefits for patients with advanced HCC with second- or later-line therapies and a high burden of intrahepatic lesions. Dose modification should be paid increased attention among patients with poor liver function, such as Child-Pugh class B patients.Liver Cancer
Source: Liver Cancer - Category: Cancer & Oncology Source Type: research
More News: Bile | Bilirubin | Cancer | Cancer & Oncology | Carcinoma | Children | Hepatocellular Carcinoma | Japan Health | Liver | Liver Cancer | Study | Urology & Nephrology